Search
 
 
NIRS FLASH!
investor

Somanetics Corporation (NASDAQ: SMTS) is the pioneer and leader of noninvasive cerebral and somatic (of the body) oximetry, providing U.S. clinicians with the first adult cerebral oximeter, the first pediatric cerebral oximeter and the first simultaneous brain and body oximeter.

The INVOS® Cerebral/Somatic Oximeter has one job: to noninvasively measure changes in site-specific blood oxygen levels to help surgical and critical care teams protect their patients against brain and vital organ-area damage or even death. As such, the INVOS® System is a vital sign for 21st century medicine.

Enlightening Facts

  • Somanetics has experienced double-digit sales growth for the last 12 years, including record revenue in 2008 of $47.5 million.

  • The INVOS® System is in use at more than 700 U.S. hospitals, including 80% of centers performing pediatric cardiac surgery, plus more than 1,200 installs internationally.

  • Surgeons, anesthesiologists, critical care nurses and many other medical professionals use the INVOS® System to better manage the hemodynamic stability of their adult, pediatric, infant and neonatal patients. These clinicians have authored or presented more than 600 papers and medical lectures describing the clinical and patient benefits they receive from the INVOS® System.

  • Somanetics' intellectual property includes 11 U.S. patents and three foreign patents related to the INVOS® System. Some of these patents cover key aspects of the technology through 2019. New INVOS® System product development and emerging application studies are continuously underway.

To contact Somanetics Investor Relations department, send e-mail to This e-mail address is being protected from spambots. You need JavaScript enabled to view it or call (248) 244-1409 or (800) 935-3731, ext 1409.